Market research
82C.F Circassia Group Plc
F EUR Healthcare
Latest close
As of 29 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 310M
- P/E ratio
- 38.25
- Analyst target
- Not available
- Dividend yield
- 2.0%
- Beta
- -0.04
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- GB00BJVD3B28
- Market cap
- 310M
- P/E ratio
- 38.25
- Analyst target
- Not available
- Dividend yield
- 2.0%
- Beta
- -0.04
About
About Circassia Group Plc
NIOX Group Plc engages in the design, development, and commercialization of medical devices for the diagnosis, monitoring, and management of asthma and COPD worldwide. The company offers NIOX VERO, a non-invasive and point-of-care system that comprises a small portable device, sensors, individual disposable mouthpieces, and breathing handles for the measurement of fractional exhaled nitric oxide (FeNO) level in patients. The company was formerly known as Circassia Group Plc and changed its name to NIOX Group Plc in September 2022. NIOX Group Plc was incorporated in 2006 and is headquartered in Oxford, the United Kingdom.
Research context
Circassia Group Plc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Devices
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 82C.F discussion.
5 years, 7 months ago
Circassia Group Plc is currently in a long term uptrend where the price is trading 8.3% above its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.3.
Finally, its free cash flow grew by 34.3% to $-2M since the same quarter in the previous year.
Based on the above factors, Circassia Group Plc gets an overall score of 3/5.